|Bid||39.00 x 1100|
|Ask||43.14 x 800|
|Day's Range||41.00 - 43.15|
|52 Week Range||14.30 - 51.67|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
Krystal Biotech Inc (NASDAQ: KRYS ) announced positive Phase 2 data for KB103 Monday and said the gene therapy received the Regenerative Medicine Advanced Therapy designation from the FDA. The Phase 2 ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
Krystal Biotech Inc (NASDAQ: KRYS ) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday. The stock was higher by 46.11% at $42.59 at the time ...
The Pittsburgh-based gene therapy company plans to launch phase three of the trial before the end of 2019.
Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had received an expedited review designation from the FDA for its lead drug candidate to treat a skin condition called dystrophic epidermolysis bullosa. The condition, which involves severe blistering due to a lack of collagen in the skin, is currently incurable. Krystal's drug, called KB102, is a viral vector that delivers human COL7A1 genes -- which code for functional collagen -- directly to the patient's cells. The company also announced some positive results from a Phase 2 trial looking at six blister wounds being treated with KB103 -- five closed up completely, and the drug was well-tolerated, Krystal said. No serious adverse events or drug-related adverse events were reported, and there were no reports of inflammation or irritation in the KB103-treated wounds, the company said. Shares of Krystal have gained 76% in the year to date, while the S&P 500 has gained 17.8%.
Danforth Advisors, a Boston-area provider of financial and accounting services to the life sciences sector, has entered Pittsburgh. Founded in 2011, Danforth employs a team of consultants who are experienced accountants, corporate controllers and chief financial officers and specialists in financial planning and analysis. “Biotech companies are often pre-revenue stage and trying to build a business focused on science and getting things into the clinics,” said Robert Dickey IV, who joined Danforth last summer as managing director, Mid-Atlantic Region.
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 25,000 shares of KRYS on 10/18/2018 at an average price of $20 a share.